India’s pharma sector continued its robust performance in July 2026, with a 12.1% rise in value driven by premium therapies, new launches, and pricing strategies, despite subdued unit growth, according to PharmaTrac’s latest review.
India’s pharmaceutical market continued its strong run in July 2026, with industry value rising 12.1% from a year earlier even as unit growth remained subdued at 1.6%, underscoring how much of the sector’s expansion is still being driven by pricing, new launches and premium therapies, according to PharmaTrac’s latest monthly review.
The gap between value growth and volume growth remained stark on a moving annual total basis. PharmaTrac said the market expanded 10.2% in value terms over the 12 months to July, while unit growth was only 1.1%, suggesting that the industry’s headline momentum is being supported more by mix and pricing than by broad-based consumption. The report also indicated that July’s value growth was a step up from the earlier pace of 7.3%, strengthening the impression that the market has carried its double-digit trajectory into the second half of the year.
Therapy-wise, cardiac treatments were the largest category by sales at Rs 3,299 crore and advanced 14.7%. Gastro intestinal drugs followed at Rs 2,820 crore, with anti-infectives at Rs 2,470 crore. Anti-diabetic therapies grew 17.6% to Rs 2,237 crore, while vitamins, minerals and nutrients rose 15.7% to Rs 2,206 crore. Respiratory medicines climbed 11.2%, pain and analgesics 11.4% and neuro/CNS 13.4%, while vaccines and anti-neoplastics were among the fastest-growing segments, up 17.5% and 21.1% respectively.
At brand level, Eli Lilly’s Mounjaro stood out, with sales of Rs 1,228 crore and growth of 880%, adding Rs 1,103 crore, the report said. The latest figures build on a broader pattern seen across 2026, when the market has repeatedly posted double-digit growth and analysts have pointed to a mix of stronger chronic-therapy demand, higher prices and new product introductions as the main engines of expansion. Even so, the modest unit trend suggests the market’s strength is still not evenly spread across volumes.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
